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Summary Carcinoembryonic antigen (CEA) is one of the most important tumour markers in the manage-
ment of human carcinoma, including lung cancer. So far, however, because of the nonspecificity of anti-CEA
antibodies, it remains unclear whether the experimental measurements of CEA expression really reflect genuine
CEA. In normal lung, nonspecific cross reacting antigen (NCA) has been described as a major component of
CEA-related antigens. Recently isolated CEA and NCA cDNA clones enabled us to analyse CEA and NCA
expression of in vivo tumour specimens and tumour cell lines at mRNA levels. NCA-specific mRNA (but not
CEA-specific mRNA) was detected in all normal lung tissues examined. Of 21 lung cancer tissue specimens,
nine expressed both NCA and CEA and five expressed only NCA. Of 16 tumour cell lines, two expressed only
NCA and one expressed both NCA and CEA, although its level of CEA mRNA was weaker than that of
NCA mRNA. Therefore, CEA-related mRNA expression was always accompanied by NCA mRNA expres-
sion; there were no cases of CEA mRNA expression alone. These findings suggest that NCA is a major
member of the CEA-related gene family expressed in lung cancer.
Carcinoembryonic antigen (CEA), which was first described
in 1965 as a colon tumour-specific antigen (Gold & Freed-
man, 1965), is an important clinical marker of lung cancer in
serum (Gail et al., 1988), pleural effusion (Booth et al., 1977;
Rittgers et al., 1978) and bronchoalveolar lavage fluid
(BALF) (Lemarie et al., 1980; Goldstein et al., 1985). The
CEA concentrations in serum (Stevens & Mackay, 1973) and
BALF (Merrill et al., 1981) of smokers are higher than those
of nonsmokers, and patients with idiopathic pulmonary
fibrosis demonstrate a high level of CEA in BALF
(Takahashi et al., 1985). These analyses were made by anti-
CEA antibodies. However, some anti-CEA antibodies,
especially polyclonal antibodies, also react with nonspecific
crossreacting antigen (NCA), a CEA-related glycoprotein
and a major component of the CEA family in the lung (von
Kleist et al., 1972; Mach & Pusztaszeri, 1972). As far as we
know, the target of these antibodies was so-called CEA, a
compound of genuine CEA and NCA, and there has been
little discussion about the relevance of NCA, especially at the
mRNA level.
Recently, CEA (Oikawa et al., 1987a; Zimmermann et al.,
1987; Kamarck et al., 1987; Beauchemin et al., 1987) and
NCA (Oikawa et al., 1987b; Tawaragi et al., 1988; Neumaier
et al., 1988) cDNA clones were isolated and characterised.
DNA analysis indicated that both of them are in the
immunoglobulin superfamily (Oikawa et al., 1987c; Paxton et
al., 1987). The development of CEA and NCA-specific DNA
probes enabled us to discriminate the expression of CEA and
NCA at the mRNA level. In this paper, we describe various
patterns of CEA and NCA mRNA expression in lung cancer
cell lines and in vivo specimens.
at Nagoya University Hospital, Nagoya, Japan. Cancer types
are listed in Table I.
Cell lines
Lung cancer cell lines A549 (adenocarcinoma), RERF-LC-
MA (small cell), RERF-LC-MS (adenocarcinoma), SBC-2
(small cell), SBC-3 (small cell), EBC-1 (squamous cell), and
PC-3 (adenocarcinoma) and stomach cancer cell line Kato III
were obtained from the Japanese Cancer Research Resources
Bank. Lung cancer cell lines ACC-LC-170, 76, 67, 49, 177, 48
(small cell), SK-LC-4, 10 (adenocarcinoma) and Calu 6 (large
cell) were obtained from Aichi Cancer Center (Dr T.
Takahashi), Nagoya, Japan. Chinese hamster ovary (CHO)
transformants expressing only CEA or NCA were established
as previously described (Oikawa et al., 1989). Each cell line
was cultured in RPMI 1640 medium supplemented with 10%
foetal calf serum.
DNA probe
The CEA DNA probe, which hybridised with the 4.2kb,
3.5kb (CEA) and 2.9kb (NCA) mRNAs, is a PvuII-digested
DNA fragment of the pCEA 55-2 clone, CEA3 (Sato et al.,
1988) (Figure 1). The EcoRI-digested DNA fragment of the
3'-untranslated region of NCA clone 15 (Tawaragi et al.,
1988) was used as the NCA-specific DNA probe; it hyb-
ridised with the 2.9kb (NCA) mRNA (Figure 1). Human
,-actin probe (Nakajima-Tijima et al., 1985) was used as an
internal control.
Materials and methods
Tumour and nontumour specimensfrom lung cancer patients
Twenty-one lung cancer tissue specimens and six normal lung
tissue specimens were obtained from fresh surgical specimens
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Table I Characteristics of the patients
Tissue type Pt. No.
Squamous cell Pt. 1, 5, 6, 7, 9, 10, 12, 13, 17, 18
Adenocarcinoma Pt. 3, 4, 8, 11, 15, 16, 19, 20, 21
Small cell Pt. 2
Mucoepidermoid Pt. 14
Normal lung Pt. 1, 2, 3, 4, 5, 6
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Figure 1 CEA and NCA DNA probes used in the present study
and the position of the RT-PCR product.
DNA primer
A pair of DNA primers, 5'-GACAGCTTTTCCCAAGA-
TGT-3' (primer a) and 5'-AGTCTAGAAGTCCAACT-CTG-
3' (primer b), was used to amplify the 303-bp NCA-specific
fragment of the 3'-untranslated region of NCA mRNA. The
position of the primer is shown in Figure 1.
RNA isolation and Northern blot analysis
Total RNA was extracted from each cell line and lung tissue
specimen following the methods described in the literature
(Chomczynski & Sacchi, 1987). About 10ytg of each RNA
preparation was electrophoresed on 1% agarose gels contain-
ing 1.1 M formaldehyde. The RNA was transferred to
Hybond-N nylon membranes (Amersham). mRNA was
detected by 32P-labelled probe (Multiprime labeling system,
Amersham) by hybridisation for 18 h at 420C in 5 x SSPE
(1 x SSPE is composed of 0.18 M NaCl, 10 mm sodium phos-
phate (pH 7.7), and 1 mM EDTA), 5 x Denhardt's solution
(1 x Denhart's solution is composed of 0.02% bovine serum
albumin, 0.02% Ficoll, and 0.02% polyvinyl pyrollidone),
50% formamide, 0.1% sodium dodecyl sulphate (SDS), 50 pg
ml-' heat-denatured salmon testis DNA, and radioactive
probe. Membranes were washed twice for 15 min at 65°C in a
solution containing 2 x SSC (1 x SSC is composed of 0.15 M
NaCI and 15 mM sodium citrate) and 0.1% SDS, then once
in 1 x SSC with 0.1% SDS for 30 min at 65°C, and finally
twice for 15 min in 0.1% SSC with 0.1% SDS at room
temperature. The membranes were then autoradiographed at
- 70°C using Fuji RX film.
Reverse transcriptase polymerase chain reaction (RT-PCR)
The total RNA extracts of some lung cancer cell lines and in
vivo lung cancer tissue specimens were first treated with
DNase I (Takara) to eliminate contamination of the genomic
DNA. After inactivation at 940C for 5 min, RNA was then
converted to cDNA by RT (RAV-2; Takara) at 42°C for
30 min with the primer b mentioned above. Again inactivated
at 94°C for 5 min, the samples were amplified with primer a
and Taq DNA polymerase (Promega). They were ther-
mocycled at 940C for 40 s, 55°C for 45 s, and 72°C for 1 min
(40 cycles). PCR amplification products were evaluated by
3% agarose gel electrophoresis followed by Southern hyb-
ridisation using the NCA-specific probe. The hybridisation
protocol was the same as that mentioned for Northern hyb-
ridisation.
Immunohistochemical analysis
The tissues were promptly fixed in periodate-lysine 4%
paraformaldehyde for 6 h, washed in phosphate-buffered
saline (PBS) containing increasing concentrations of sucrose,
frozen in OCT compound (Lab Tek Products), and sectioned
6 gm thick on a cryostat. The sections were placed on egg-
albumin coated slides and dried in air. Rabbit anti-human
CEA polyclonal antibody (DAKO) was used as the first
antibody. The goat anti-rabbit F(ab')2 fragment of immunog-
lobulin G (IgG) labelled with horseradish peroxidase
(Organon Teknika) was used as the second antibody. Cryos-
tat sections to be observed by light microscopy were treated
with 100% methanol containing 0.03% hydrogen peroxidase
to inactivate endogenous peroxidase. The indirect horseradish
peroxidase-labelled antibody method was used for the
immunological reaction, as previously described (Nagura et
al., 1986; Yamamoto et al., 1988). Briefly, the procedure
involved successive incubations with or without the first
antibody in optimal dilutions for 12 h at 4°C and the second
antibody for 6 h at 4°C. Sections were then treated with
0.25% diaminobenzidine (DAB) solution containing 0.01 M
sodium azide and 0.01 M hydrogen peroxide and counter-
stained with methyl green.
Immunofluorescence and laserflow cytometry
Indirect immunofluorescence analysis was performed using
anti-human CEA polyclonal antibody (DAKO) as the first
antibody and fluorescein isothiocyanate (FITC)-conjugated
anti-rabbit IgG goat antiserum (Organon Teknika) as the
second antibody. The cell lines reacted with the first antibody
for 1 h at 4°C. After three washings, cells were suspended in
the medium containing the second antibody and incubated
for 1 h at 4°C. The stained cells were resuspended in the
medium after three washings and analysed on an EPICS
profile flow cytometer (Coulter Corp.).
Immunoblotting analysis
About 107 of some lung cancer cell lines were washed with
PBS and homogenised. Extracts were sonicated, and 10fL of
each homogenate (about 10jig) was resolved by 7.5% SDS-
polyacrylamide gel electrophoresis (PAGE). The proteins
were electrophoretically transferred to nitrocellulose memb-
ranes and visualised with rabbit anti-human CEA antibody
(DAKO).
Results
Confirmation ofspecificity ofNCA probe
Northern hybridisation analysis was used to confirm the
specificity of the NCA probe. We analysed the thymuses of
CEA-transgenic mice established by us (Hasegawa et al.,
1991) and the Kato III tumour cell line. When we used the
CEA probe, we could detect CEA mRNA in the transgenic
mice's thymuses (data not shown) as mentioned before
(Hasegawa et al., 1991) and 4.2, 3.5, and 2.9kb mRNAs in
Kato III (Figure 2). However, when we used the NCA probe,
we could not detect any mRNA in the CEA-transgenic mice's
thymuses or in normal B6 mice's thymuses (Figure 3), but we
could detect one band (2.9kb) of mRNA in Kato III (Figure
3). The CEA probe we used hybridised not only with CEA
but also with NCA mRNA, because the probe recognised the
NCA coding region that has very high homology with the
CEA coding region. From these results, we confirmed that
the CEA probe hybridised with CEA (4.2, 3.5kb) and NCA
(2.9kb) mRNAs and that the NCA probe hybridised only
with NCA (2.9kb) mRNA.
Expression ofNCA and CEA mRNAs in lung cancer cell lines
Cell lines A549 and PC3 expressed 2.9kb NCA mRNA, but
not 4.2 or 3.5kb CEA mRNAs when CEA (Figure 2) and
NCA (Figure 3) probes were used. Cell line SK-LC-10 exp-
ressed 4.2, 3.5, and 2.9kb mRNAs (Figure 2), although the
4.2 and 3.5kb mRNAs were weaker than the 2.9kb mRNA.
The other cell lines expressed neither CEA nor NCA mRNA
(Figures 2, 3).
Expression ofNCA and CEA mRNAs in tissue specimens
We analysed the expression of NCA and CEA mRNAs in
cancer tissues and adjacent noncancerous lung tissues. All
noncancerous lung tissues examined expressed 2.9kb mRNA
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Figure 2 Northern blot analysis of CEA and NCA in lung cancer cell lines by the CEA DNA probe. About g of total RNA
was electrophoresed on a formaldehyde-agarose gel, transferred to a nylon membrane, and hybridised with the 32P-labelled Pvull
fragment of CEA cDNA. After hybridisation, the filters were washed as described in the 'Materials and methods' section and
autoradiographed. The same filters were rehybridised with human P-actin probe, and the results are shown at the bottom of the
figure.
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Figure 3 Northern blot analysis ofNCA in lung cancer cell lines by the NCA-specific DNA probe. The procedure was the same as
that described in Figure 2.
but not 4.2 or 3.5kb mRNAs (Figure 4a). Among 10
squamous cell lung cancer specimens, six expressed both
NCA and CEA mRNAs (Figures 4b, c, Pts 1, 6, 9, 10, 12,
18), one expressed only NCA mRNA (Figure 4c, Pt 7), and
the others expressed neither (Figures 4b, c, Pts 5, 13, 17). Of
the adenocarcinomas, three expressed both NCA and CEA
mRNAs (Figure 4c, Pts 11, 16, 19), four expressed only NCA
mRNA (Figures 4b, c, Pts 3, 4, 20, 21), and the others
expressed neither (Figure 4c, Pts 8, 15). One small-cell lung
cancer specimen (Figure 4b, Pt2) and one mucoepidermoid
lung cancer (Figure 4c, Pt 14) specimen expressed neither.
From these results, we concluded that if the CEA-related
genes were expressed in the lung, they always include NCA,
but only occasionally include CEA. The NCA-specific probe
confirmed these results (Figure 5). The analyses of cell lines
and in vivo specimen are summarised in Tables II and
III.
Detection ofNCA mRNA transcripts using RT-PCR
To confirm the negative expression of NCA in lung cancer
cell lines and tissue specimens, we carried out RT-PCR. As
shown in Figure 6a, we could clearly detect NCA PCR
products in cell lines A549, PC-3, and SBC-2 and weak
bands in cell lines EBC-1 and RERF-LC-MS. We could not
detect NCA-specific PCR products in cell lines SBC-3 and
RERF-LC-MA, although we could observe a nonspecific
DNA band by ethidium bromide staining. On the other
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Figure 4 a, Northern blot analysis of CEA and NCA of in vivo noncancerous lung tissues by the CEA DNA probe. b, c, Northern
blot analysis of CEA and NCA of in vivo lung cancer tissues by the CEA DNA probe. The procedures were the same as those
described in Figure 2.
hand, we could detect NCA PCR products in all the tissue
specimens examined (Pts 12-20). As shown in each figure,
we were able to rule out the possibility of contamination of
genomic DNA by the negative PCR product of DNase I-
treated genmomic A549 DNA.
CEA and/or NCA expression atprotein level
The in vivo specimens that we analysed contained various
kinds of cells. To clarify CEA and/or NCA protein expres-
sion at the cellular level, we did immunohistochemical
analysis. As shown in Figure 7a, the stained cells in non-
cancerous lung tissues of patient 3 were mostly epithelial
cells; stromal tissues and muscle were not stained. Figure 7b
shows an example of the lung cancer tissue (again, patient 3).
In this case, the stromal cells were dominant and the cancer
cells were scattered, but only the cancer cells were stained.
Moreover, we could hardly see normal epithelial cells in
cancer tissues. These findings convinced us that the result of
the Northern blot analysis reflected well the mRNA expres-
sion of noncancerous lung tissue and lung cancer cells.
In addition, as shown in Figure 8, cell line A549, which
expressed only NCA mRNA, reacted to the anti-CEA polyc-
lonal antibody (Figure 8b) as did cell line Kato III, which
expressed both NCA and CEA mRNAs (Figure 8a). Cell line
SBC-2, which expressed a very low level of NCA detected
only by sensitive RT-PCR, had almost no reactivity with the
anti-CEA polyclonal antibody (Figure 8c).
Our final analysis was a Western blot. As shown in Figure
9, we clearly detected a 50- to 130-kDa protein in cell line
A549 and in the NCA-transformant CHO cell line. In cell
lines PC3 and Kato III we could detect both CEA and NCA
proteins. In cell lines SBC-2 and A549 we could detect a
200-kDa band, which might have been a CEA band, weakly.
In cell lines EBC-1 and RERF-LC-MS, we could not detect a
protein band, although we could detect NCA RT-PCR prod-
ucts.
Discussion
CEA is one of the most important tumour markers in
patients with cancer, including lung cancer. In clinical
analysis polyclonal antibodies are usually used, which also
react with non-CEA products. Even if we analyse CEA
expression with monoclonal antibodies, there are at least five
groups of antibodies that recognise different epitopes (NCA-
common, normal foecal crossreacting antigen-common, nor-
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Figure 5 a, Northern blot analysis of NCA of in vivo noncancerous lung tissues by the NCA-specific DNA probe. b, c, Northern
blot analysis of NCA of in vivo lung cancer tissues by the NCA-specific DNA probe. The procedures were the same as those
described in Figure 2.
Table II CEA and NCA mRNA expression in lung cancer cell
lines
Type of lung cancer Positive cell lines/No. examined
NCA&CEA NCA only Not detected
Squamous cell 0/1 0/1 1/1
Adenocarcinoma 1/5 2/5 2/5
Small cell 0/9 0/9 9/9
Large cell 0/1 0/1 1/1
Total 1/16 2/16 13/16
mal foecal antigen-I-common, heterogenous, and CEA-
distinctive antibodies) (Kuroki et al., 1987). It is still difficult
to use NCA-specific antibodies that do not react with the
CEA molecule. Moreover, there is a possibility that some
monoclonal antibodies could not react with the CEA or
NCA molecules of cells in which we detected CEA or NCA
mRNA because of glycosylation or three-dimensional confor-
Table III CEA and NCA mRNA expression in lung cancer
specimens
Type of lung cancer Positive specimens/No. examined
NCA&CEA NCA only Not detected
Squamous cell 6/10 1/10 3/10
Adenocarcinoma 3/9 4/9 2/9
Small cell 0/1 0/1 1/1
Mucoepidermoid 0/1 0/1 1/1
Total 9/21 5/21 7/21
mation change. Because of these nonspecificities of the anti-
CEA antibodies and the lack of NCA-specific antibodies that
are confirmed to react only with NCA and never with CEA,
few investigators have been able to analyse CEA and NCA
separately in lung diseases at either the protein or mRNA
levels. Considering that NCA is a major component of
diseased lung cells, analysis for CEA alone may not be
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Figure 6 a, RT-PCR of lung cancer cell lines. Gel electrophoresis of RT-PCR reaction products (40 cycles of amplification) of a
303-bp NCA RNA (upper). Southern blot analysis of the same samples hybridised with the NCA-specific probe (lower). b,
RT-PCR of tissue specimens. Gel electrophoresis of RT-PCR reaction products (40 cycles of amplification) of a 303-bp NCA RNA
(upper). Southern blot analysis of the same samples hybridised with the NCA-specific probe (lower).
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Figure 7 Immunohistochemical analysis of in vivo specimens. a,
Noncancerous lung tissues of patient 3. b, Lung cancer tissues of
patient 3. Both tissues were stained with rabbit anti-CEA polyc-
lonal antibody (DAKO). Magnification: a, x 200; b, x 100.
sufficient in lung diseases. If genuine CEA is elevated in some
lung diseases, it is possible that NCA is also elevated in those
diseases.
The recent development of an NCA-specific DNA probe
enabled us to study these problems. We examined CEA
mRNA and NCA mRNA expression separately by Northern
Figure 8 CEA expression on the cell surfaces of lung cancer cell
lines. Cells were stained by the indirect immunofluorescence
method and analysed by flow cytometry. a, Kato III; b, A549; c,
SBC-2. Each solid line is the result with both the first and second
antibodies. Broken lines represent the results without the first
antibody.
blot analysis without considering glycosylation or three-
dimensional conformation changes, which are difficult to
analyse even if many types of anti-CEA or NCA-specific
monoclonal antibodies are used.
Most colon carcinomas express bQth CEA and NCA
mRNA (Sato et al., 1988; Cournoyer et al., 1988), but this
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Figure 9 Immunoblot analysis of lung cancer cell lines and the
CHO-transformant cell line, which expressed only CEA or NCA
when anti-CEA polyclonal antibody (DAKO) was used.
study showed various patterns of CEA and NCA expression
in lung cancers. That is, the lung cancers expressed both
CEA and NCA mRNA, only NCA mRNA, or neither
mRNA by usual Northern blot analysis, irrespective of
pathologic lung cancer cell types. We could not find any lung
cancers in which only CEA mRNA was detected by North-
ern blot analysis. Moreover, although it has been reported
that noncancerous colon tissues expressed CEA and NCA,
noncancerous lung tissues expressed only NCA mRNA by
Northern blot analysis.
The in vivo specimens comprised many types of cells. We
confirmed by immunohistochemistry that the cells expressing
CEA-related genes in the lung were epithelial cells in non-
cancerous tissues. We ruled out the possibility that some
stroma tissue, mucosa, and muscle might express CEA-
related genes. These results suggest that colon and lung
tissues may have different transcriptional controls of CEA
and NCA.
We carried out RT-PCR analysis to confirm the results of
the Northern blot analysis, because the mRNA-positive per-
cent was lower than that we expected. We detected NCA
PCR products in some cancer cell lines in which we could
not detect NCA mRNA by Northern blot analysis. In cell
line A549 the results of Northern blot, RT-PCR, and
Western blot were well correlated. But the molecular size of
the protein expressed by cell lines PC-3 and SBC-2 was not
correlated with the Northern blot and RT-PCR analyses.
One possibility is that there might exist very small amounts
of CEA mRNA in both cell lines. Each CEA mRNA might
be translated to protein, but the NCA mRNA in cell line
SBC-2 might not be translated to protein. Another possibility
is that anti-CEA polyclonal antibodies react with products
other than CEA and NCA. We detected NCA PCR products
in all tissue specimens examined. One explanation is that all
lung cancers express NCA at very low levels. Another is that
normal lung tissues that express NCA are contaminated.
Finally, CEA and NCA have been described as cell-cell
adhesion molecules (Benchimol et al., 1989; Oikawa et al.,
1989), and it is possible that they play an important role in
cancer metastasis. In addition, the high lysability by LAK
cells of colon carcinoma cells resistant to doxorubicin has
been associated with NCA and not CEA (Rivoltini et al.,
1991). Therefore, the assessment of CEA and NCA expres-
sion in lung cancers may be important in determining the
prognosis of lung cancer patients.
In conclusion, lung cancer cells fall into three different
types according to their CEA and/or NCA expression by
Northern blot analysis. It is important that CEA and NCA
are estimated separately in lung cancers at the mRNA level
or the protein level.
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